



ChromaDex®

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), a coenzyme known as the central catalyst of metabolism.

ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio.

ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors.

Our Scientific Advisory Board

Charles Brenner, Ph.D.

Alfred E Mann Chair, Dept of Diabetes & Cancer Metabolism,
City of Hope National Medical
World's Foremost Authority on NAD+ Metabolism

Roger Kornberg, Ph.D.

Professor of Structural Biology, Stanford University
Nobel Prize Winner, Chemistry

Sir John Walker FRS, FMedSci

Emeritus Director & Professor MRC Mitochondrial Biology Unit, Cambridge
Nobel Prize Winner, Chemistry

TRU NIAGEN®

Tru Niagen® is our commercially available flagship product.

It bears the NSF Certified for Sport® seal, signifying that Tru Niagen® is made to current Good Manufacturing Practice (cGMP) standards and confirming the absence of over 270 athletic-banned substances and harmful contaminants.

The active ingredient behind Tru Niagen® is our patented Niagen®, nicotinamide riboside.

Oral Niagen® nicotinamide riboside is shown to increase whole blood NAD+ in a dose-dependent manner in adult humans. NAD+ is a vital coenzyme naturally produced in the body that declines with age and exposure to metabolic stress.

As of May 2021, over 75% of registered clinical studies investigating nicotinamide riboside have chosen ChromaDex to source their study material. Combined with the World Health Organization (WHO) International Clinical Trials Registry Platform, there are more than 45 ongoing or completed studies investigating Niagen® nicotinamide riboside alone or in combination with other ingredients.

Niagen® has been successfully reviewed twice under the US Food and Drug Administration's (FDA) New Dietary Ingredient Notification (NDIN) program and successfully notified to the FDA as Generally Recognized as Safe (GRAS).

Globally, Niagen® has also been reviewed and accepted by Health Canada, the European Commission, and the Therapeutic Goods Administration of Australia.

Rudolph Tanzi, Ph.D.

Kennedy Professor of Neurology, Harvard University
Leading Alzheimer's Researcher, TIME 100 Most Influential 2015

Dr. Bruce German, Ph.D.

Chairman of Food, Nutrition, & Health, University of California, Davis
Leader in Food, Nutrition, & Wellness Innovation

Brunie H. Felding, Ph.D.

Associate Professor of Molecular Medicine, Scripps Research Institute
Renowned Breast Cancer Researcher focused on NAD+ supplementation

David L. Katz, M.D., M.P.H., FACPM, FACP, FACLM

CEO of Diet ID, Inc, founder of Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine
Leading expert in nutrition, health promotion and chronic disease prevention

ChromaDex Reference Standards



ChromaDex was originally founded in 1999 as a reference standards company, a business unit that remains strong today.

We are a proud provider of phytochemical reference standards, botanical and research-grade materials, with a keen focus on natural products and moieties that support the food, beverage, and nutritional supplements space.

We now list 1800 phytochemicals and 400 botanical reference materials in our catalog, providing compound isolation and characterization services in a variety of biomass sources for academic and industry partners all over the world.

While working closely with the research community, industry partners, and governing bodies, including the AOAC International, the US Pharmacopeia (USP), and the American Herbal Products Association (AHPA), we also assure you that our standards meet yours.

The ChromaDex External Research Program (CERP)



The ChromaDex External Research Program (CERP™) is a vital arm of ChromaDex's R&D division.

Leading scientists worldwide request the use of our material for their independent preclinical and clinical research studies. Additionally, we occasionally partner with academic scientists and contract research organizations to conduct specific studies on ChromaDex's behalf.

As of May 2021, ChromaDex has agreed to supply Niagen®, in-kind, for over 225 studies, investigating the benefits of elevating NAD+ in various aspects of health. While our primary pursuit is examining NAD+ supplementation as a component of healthy aging, we are proud to support the advancement of NAD+ research in other areas, including heart, brain, liver, muscle, and kidney health.

We supply Niagen® and various other ChromaDex materials for research through a Material Transfer Agreement for outstanding research studies through a competitive application process. If you are interested in learning more about our program, please go to our website, www.chromadex.com/cerp.